C4 Therapeutic (CCCC) announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer (PFE). Under the terms of the agreement, Pfizer will supply elranatamab, a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for its upcoming Phase 1b trial. The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with multiple myeloma. This Phase 1b trial, which is expected to initiate in Q2 2026, will seek to establish an optimal dose for cemsidomide in combination with elranatamab. Under the terms of the agreement, Pfizer will supply elranatamab at no cost while C4T will sponsor and conduct the trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics price target raised to $10 from $5 at Wells Fargo
- C4 Therapeutics price target raised to $10 from $8 at Barclays
- C4 Therapeutics Reports Promising Phase 1 Trial Results
- C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market
- C4 Therapeutics presents data from Phase 1 trial of cemsidomide